{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:29:07Z","timestamp":1794670147888,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12916-018-1242-0","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T19:00:01Z","timestamp":1546974001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Monica","family":"Bolton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hodkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Boda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Panagioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Riste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"van Marwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"key":"1242_CR1","first-page":"1600","volume-title":"British National Formulary (BNF) 75 (March 2018)","year":"2018","unstructured":"Joint Formulary Committee, editor. British National Formulary (BNF) 75 (March 2018). 73rd ed. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society; 2018. p. 1600.","edition":"73"},{"key":"1242_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545\u2013602.","journal-title":"Lancet"},{"key":"1242_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459\u2013544.","journal-title":"Lancet"},{"key":"1242_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000447965","volume":"22","author":"JG Bramness","year":"2016","unstructured":"Bramness JG, Mann K, Wurst FM. Marketing status and perceived efficacy of drugs for supporting abstinence and reducing alcohol intake in alcohol use disorders: a survey among European Federation of Addiction Societies in Europe. Eur Addict Res. 2016;22:318\u201321.","journal-title":"Eur Addict Res."},{"key":"1242_CR5","doi-asserted-by":"publisher","first-page":"e0173272","DOI":"10.1371\/journal.pone.0173272","volume":"12","author":"A Thompson","year":"2017","unstructured":"Thompson A, Ashcroft DM, Owens L, van Staa TP, Pirmohamed M. Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS One. 2017;12:e0173272.","journal-title":"PLoS One."},{"key":"1242_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/acer.13594","volume":"42","author":"K Witkiewitz","year":"2018","unstructured":"Witkiewitz K, Vowles KE. Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol Clin Exp Res. 2018;42:478\u201388.","journal-title":"Alcohol Clin Exp Res."},{"key":"1242_CR7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1176\/appi.ajp.2008.08020304","volume":"165","author":"N Jayaram-Lindstr\u00f6m","year":"2008","unstructured":"Jayaram-Lindstr\u00f6m N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165:1442\u20138.","journal-title":"Am J Psychiatry."},{"key":"1242_CR8","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/j.drugalcdep.2014.09.331","volume":"146","author":"K Kampman","year":"2015","unstructured":"Kampman K, Pettinati H, Lynch K, Plebani J, Lachewitz J, Feeney K, et al. Modafinil and naltrexone for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2015;146:e152.","journal-title":"Drug Alcohol Depend."},{"key":"1242_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.4088\/JCP.v69n0511","volume":"69","author":"JE Grant","year":"2008","unstructured":"Grant JE, Kim SW. Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69:783\u20139.","journal-title":"J Clin Psychiatry."},{"key":"1242_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.biopsych.2008.11.022","volume":"65","author":"JE Grant","year":"2009","unstructured":"Grant JE, Kim SW. Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009;65:600\u20136.","journal-title":"Biol Psychiatry."},{"key":"1242_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","volume":"83","author":"K Papay","year":"2014","unstructured":"Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83:826\u201333.","journal-title":"Neurology."},{"key":"1242_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1530-0277.2007.00347.x","volume":"31","author":"SS O\u2019Malley","year":"2007","unstructured":"O\u2019Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31:625\u201334.","journal-title":"Alcohol Clin Exp Res."},{"key":"1242_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jir.12122","volume":"59","author":"A Roy","year":"2015","unstructured":"Roy A, Roy M, Deb S, Unwin G, Roy A. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. J Intellect Disabil Res. 2015;59:293\u2013306.","journal-title":"J Intellect Disabil Res."},{"key":"1242_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0024-3205(84)90651-9","volume":"35","author":"IS Zagon","year":"1984","unstructured":"Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci. 1984;35:409\u201316.","journal-title":"Life Sci."},{"key":"1242_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.intimp.2016.08.015","volume":"39","author":"Z Yi","year":"2016","unstructured":"Yi Z, Guo S, Hu X, Wang X, Zhang X, Griffin N, et al. Functional modulation on macrophage by low dose naltrexone (LDN). Int Immunopharmacol. 2016;39:397\u2013402.","journal-title":"Int Immunopharmacol."},{"key":"1242_CR16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","volume":"68","author":"BAC Cree","year":"2010","unstructured":"Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68:145\u201350.","journal-title":"Ann Neurol."},{"key":"1242_CR17","first-page":"189","volume":"3","author":"AK Traore","year":"2011","unstructured":"Traore AK, Thiero O, Dao S, Kounde FFC, Cisse M, Mccandless JB, et al. Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV + adults in Mali: a single blind randomized clinical trial. J AIDS HIV Res. 2011;3:189\u201398.","journal-title":"J AIDS HIV Res."},{"key":"1242_CR18","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","volume":"56","author":"JP Smith","year":"2011","unstructured":"Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56:2088\u201397.","journal-title":"Dig Dis Sci."},{"key":"1242_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.37734","volume":"65","author":"J Younger","year":"2013","unstructured":"Younger J, Noor N, McCue R, MacKey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529\u201338.","journal-title":"Arthritis Rheum."},{"key":"1242_CR20","first-page":"197","volume":"20","author":"KM Sturn","year":"2016","unstructured":"Sturn KM, Collin M. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients. Int J Pharm Compd. 2016;20:197\u2013201.","journal-title":"Int J Pharm Compd."},{"key":"1242_CR21","first-page":"184","volume":"34","author":"LB Weinstock","year":"2017","unstructured":"Weinstock LB, Myers TL, Shetty A. Low-dose naltrexone for the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:184\u20137.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"1242_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","volume":"154","author":"S Cao","year":"2018","unstructured":"Cao S, Lilly E, Chen ST. Variable response to naltrexone in patients with Hailey-Hailey disease. JAMA Dermatology. 2018;154:362\u20133.","journal-title":"JAMA Dermatology."},{"key":"1242_CR23","volume-title":"announces exclusive agreement for sale of lodonal in Kenya valued at over $31 million","author":"Immune Therapeutics Inc. Immune Therapeutics, Inc","year":"2017","unstructured":"Immune Therapeutics Inc. Immune Therapeutics, Inc. announces exclusive agreement for sale of lodonal in Kenya valued at over $31 million. 2017. https:\/\/www.immunetherapeutics.com\/2017\/09\/immune-therapeutics-inc-announces-exclusive-agreement-for-sale-of-lodonal-in-kenya-valued-at-over-31-million\/ . Accessed 7 Oct 2017."},{"key":"1242_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/pds.4110","volume":"26","author":"G Raknes","year":"2017","unstructured":"Raknes G, Sm\u00e5brekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. Pharmacoepidemiol Drug Saf. 2017;26:136\u201342.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"1242_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/ecco-jcc\/jjy008","volume":"12","author":"G Raknes","year":"2018","unstructured":"Raknes G, Simonsen P, Sm\u00e5brekke L. The effect of low dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. J Crohns Colitis. 2018;12:677\u201386.","journal-title":"J Crohns Colitis."},{"key":"1242_CR26","unstructured":"House of Commons. House of Commons Deb (29 Jun 2009, vol. 495, col. 88W\u201389W) https:\/\/publications.parliament.uk\/pa\/cm200809\/cmhansrd\/chan101.pdf . Accessed 12 Dec 2018"},{"key":"1242_CR27","unstructured":"U.S. Food and Drug Administration. Safety Information - Revia (naltrexone HCl) tablets: safety labeling changes approved by FDA Centre for Drug Evaluation and Research (CDER). MedWatch Safety Information. U.S.: Department of Health and Human Services; 2013. https:\/\/wayback.archive-it.org\/7993\/20161023084600\/http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm374896.htm . Accessed 7 Oct 2017"},{"key":"1242_CR28","first-page":"66","volume":"67","author":"DN Pfohl","year":"1986","unstructured":"Pfohl DN, Allen JI, Atkinson RLRL, Knopman DS, Malcolm RJ, Mitchell JE, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986;67:66\u201372 https:\/\/archives.drugabuse.gov\/sites\/default\/files\/monograph67.pdf . Accessed 12 Dec 2018.","journal-title":"NIDA Res Monogr."},{"key":"1242_CR29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/archpsyc.1997.01830240090013","volume":"54","author":"RS Croop","year":"1997","unstructured":"Croop RS, Faulkner EB, Labriola DF. for the Naltrexone Usage Study Group. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicentre usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130\u20135.","journal-title":"Arch Gen Psychiatry."},{"key":"1242_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/13556210410001674130","volume":"9","author":"C Brewer","year":"2004","unstructured":"Brewer C, Wong VS. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol. 2004;9:81\u20137.","journal-title":"Addict Biol."},{"key":"1242_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jama.285.4.437","volume":"285","author":"JP Ioannidis","year":"2001","unstructured":"Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437\u201343.","journal-title":"JAMA."},{"key":"1242_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6904-1-3","volume":"1","author":"YK Loke","year":"2001","unstructured":"Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol. 2001;1:3.","journal-title":"BMC Clin Pharmacol."},{"key":"1242_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JPA Ioannidis","year":"2004","unstructured":"Ioannidis JPA, Evans SJW, G\u00f8tzsche PC, O\u2019Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781\u20138.","journal-title":"Ann Intern Med."},{"key":"1242_CR34","first-page":"352","volume":"i157","author":"L Zorzela","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;i157:352.","journal-title":"BMJ."},{"key":"1242_CR35","first-page":"7","volume":"C302","author":"European Commission","year":"2012","unstructured":"European Commission. Commission Guideline - Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726\/2004 and Article 41(2) of Regulation (EC) No 1901\/2006. J Eur Union. 2012;C302:7\u201310.","journal-title":"J Eur Union"},{"key":"1242_CR36","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","volume":"375","author":"DA Zarin","year":"2016","unstructured":"Zarin DA, Tse T, Williams RJ, Carr S. Special report. Trial reporting in ClinicalTrials.gov \u2013 the final rule. N Engl J Med. 2016;375:1998\u20132004.","journal-title":"N Engl J Med."},{"key":"1242_CR37","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40264-016-0416-y","volume":"39","author":"JMA Sinclair","year":"2016","unstructured":"Sinclair JMA, Chambers SE, Shiles CJ, Baldwin DS. Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf. 2016;39:627\u201345.","journal-title":"Drug Saf."},{"key":"1242_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/phar.2086","volume":"38","author":"DK Patten","year":"2018","unstructured":"Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38:382\u20139.","journal-title":"Pharmacotherapy"},{"key":"1242_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13011-015-0004-7","volume":"10","author":"RA Johnson","year":"2015","unstructured":"Johnson RA, Lukens JM, Kole JW, Sisti DA. Views about responsibility for alcohol addiction and negative evaluations of naltrexone. Subst Abuse Treat Prev Policy. 2015;10:10.","journal-title":"Subst Abuse Treat Prev Policy."},{"key":"1242_CR40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1177\/1557988315576775","volume":"11","author":"S-E Brown","year":"2017","unstructured":"Brown S-E, Vagenas P, Konda KA, Clark JL, Lama JR, Gonzales P, et al. Men who have sex with men in Peru: acceptability of medication-assisted therapy for treating alcohol use disorders. Am J Mens Health. 2017;11:1269\u201378.","journal-title":"Am J Mens Health."},{"key":"1242_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.alcohol.2006.05.003","volume":"38","author":"MH Yen","year":"2006","unstructured":"Yen MH, Ko HC, Tang FI, Lu RB, Hong JS. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 2006;38:117\u201320.","journal-title":"Alcohol."},{"key":"1242_CR42","first-page":"151","volume":"38","author":"M McDonough","year":"2015","unstructured":"McDonough M. Naltrexone and liver disease. Aust Prescr. 2015;38:151.","journal-title":"Aust Prescr."},{"key":"1242_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.18773\/austprescr.2015.015","volume":"38","author":"P Crowley","year":"2015","unstructured":"Crowley P. Author\u2019s response. Aust Prescr. 2015;38:151.","journal-title":"Aust Prescr."},{"key":"1242_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/bmj.328.7438.518","volume":"328","author":"K McPherson","year":"2004","unstructured":"McPherson K, Hemminki E. Synthesising licensing data to assess drug safety. BMJ. 2004;328:518\u201320.","journal-title":"BMJ."},{"key":"1242_CR45","volume-title":"Building a culture of candour: a review of the threshold for the duty of candour and of the incentives for care organisations to be candid","author":"D Dalton","year":"2014","unstructured":"Dalton D, Williams N. Building a culture of candour: a review of the threshold for the duty of candour and of the incentives for care organisations to be candid. London: Royal College of Surgeons of England; 2014."},{"key":"1242_CR46","unstructured":"Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). Chichester: Wiley; 2011. http:\/\/handbook.cochrane.org"},{"key":"1242_CR47","volume-title":"EudraLex volume 10: Clinical trials. EudraLex","author":"European Commission","year":"2006","unstructured":"European Commission. EudraLex volume 10: Clinical trials. EudraLex. Luxembourg: Publications Office of the European Union; 2006."},{"key":"1242_CR48","first-page":"01","volume":"C172","author":"European Commission","year":"2011","unstructured":"European Commission. Detailed guidance on the collection, verification and presentation of adverse event\/reaction reports arising from clinical trials on medicinal products for human use (\u201cCT-3\u201d). J Eur Union. 2011;C172:01\u201313.","journal-title":"J Eur Union"},{"key":"1242_CR49","volume-title":"Safety reporting requirements for INDs and BA\/BE studies","author":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry and investigators","year":"2012","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry and investigators. Safety reporting requirements for INDs and BA\/BE studies. Silver Springs: FDA; 2012."},{"key":"1242_CR50","volume-title":"Clinical safety data management: definitions and standards for expedited reporting E2A","author":"ICH Harmonised Tripartite Guideline","year":"1994","unstructured":"Harmonised Tripartite Guideline ICH. Clinical safety data management: definitions and standards for expedited reporting E2A. Geneva: ICH; 1994."},{"key":"1242_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-7-32","volume":"7","author":"YK Loke","year":"2007","unstructured":"Loke YK, Price D, Herxheimer A, the Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7:32.","journal-title":"BMC Med Res Methodol."},{"key":"1242_CR52","unstructured":"Loke YK, Price D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. London: The Cochrane Collaboration; 2011. http:\/\/handbook.cochrane.org ."},{"key":"1242_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2288-1-7","volume":"1","author":"S Derry","year":"2001","unstructured":"Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol. 2001;1:7.","journal-title":"BMC Med Res Methodol."},{"key":"1242_CR54","unstructured":"Higgins J, Altman D, Sterne JAC, editors. Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. London: The Cochrane Collaboration; 2011. http:\/\/handbook.cochrane.org"},{"key":"1242_CR55","unstructured":"Deeks J, Higgins J, Altman D, (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. London: The Cochrane Collaboration; 2011. http:\/\/handbook.cochrane.org ."},{"key":"1242_CR56","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351\u201375.","journal-title":"Stat Med."},{"key":"1242_CR57","doi-asserted-by":"publisher","first-page":"578","DOI":"10.7326\/0003-4819-147-8-200710160-00182","volume":"147","author":"GA Diamond","year":"2007","unstructured":"Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578\u201381.","journal-title":"Ann Intern Med."},{"key":"1242_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. the PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med."},{"key":"1242_CR59","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.amjmed.2004.04.026","volume":"117","author":"PN Papanikolaou","year":"2004","unstructured":"Papanikolaou PN, Ioannidis JPA. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med. 2004;117:582\u20139.","journal-title":"Am J Med."},{"key":"1242_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d. Lancet. 2005;365:82\u201393.","journal-title":"Lancet."},{"key":"1242_CR61","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","volume":"340","author":"JJ Kirkham","year":"2010","unstructured":"Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.","journal-title":"BMJ."},{"key":"1242_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jama.2013.285634","volume":"311","author":"JE Becker","year":"2014","unstructured":"Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in clinicaltrials.gov and high-impact journals. JAMA. 2014;311:1063\u20135.","journal-title":"JAMA."},{"key":"1242_CR63","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings. JAMA. 2014;311:1889\u2013900.","journal-title":"JAMA."},{"key":"1242_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/alcalc\/agv015","volume":"50","author":"PA Spagnolo","year":"2015","unstructured":"Spagnolo PA, Colloca L, Heilig M. The role of expectation in the therapeutic outcomes of alcohol and drug addiction treatments. Alcohol Alcohol. 2015;50:282\u20135.","journal-title":"Alcohol Alcohol."},{"key":"1242_CR65","first-page":"MR000035","volume":"10","author":"MJ Page","year":"2014","unstructured":"Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev. 2014;10:MR000035.","journal-title":"Cochrane Database Syst Rev."},{"key":"1242_CR66","first-page":"CD001867","volume":"12","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.","journal-title":"Cochrane Database Syst Rev."},{"key":"1242_CR67","volume-title":"Estimates of alcohol dependence in England based on APMS 2014, including estimates of children living in a household with an adult with alcohol dependence. Prevalence, trends and amenability to treatment","author":"R Pryce","year":"2017","unstructured":"Pryce R, Buykx P, Gray L, Stone T, Drummond C, Brennan A. Estimates of alcohol dependence in England based on APMS 2014, including estimates of children living in a household with an adult with alcohol dependence. Prevalence, trends and amenability to treatment. London: Public Health England; 2017."},{"key":"1242_CR68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/10550880902772456","volume":"28","author":"D Walters","year":"2009","unstructured":"Walters D, Connor JP, Feeney GFX, Young RM. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. J Addict Dis. 2009;28:137\u201344.","journal-title":"J Addict Dis."},{"key":"1242_CR69","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/MLR.0b013e3181ca3d40","volume":"48","author":"LJ Dunlap","year":"2010","unstructured":"Dunlap LJ, Zarkin GA, Bray JW, Mills M, Kivlahan DR, McKay JR, et al. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective. Med Care. 2010;48:306\u201313.","journal-title":"Med Care."},{"key":"1242_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.euroneuro.2012.08.001","volume":"23","author":"J Rehm","year":"2013","unstructured":"Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013;23:89\u201397.","journal-title":"Eur Neuropsychopharmacol."},{"key":"1242_CR71","doi-asserted-by":"publisher","first-page":"e003436","DOI":"10.1136\/bmjopen-2013-003436","volume":"3","author":"A Hodkinson","year":"2013","unstructured":"Hodkinson A, Kirkham JJ, Tudur-Smith C, Gamble C. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open. 2013;3:e003436.","journal-title":"BMJ Open."},{"key":"1242_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bph.12589","volume":"172","author":"B Afsharimani","year":"2015","unstructured":"Afsharimani B, Doornebal CW, Cabot PJ, Hollmann MW, Parat MO. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol. 2015;172:251\u20139.","journal-title":"Br J Pharmacol."},{"key":"1242_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/alcalc\/35.1.91","volume":"35","author":"J Budzy\u0144ski","year":"2000","unstructured":"Budzy\u0144ski J, Rybakowski J, Swiatkowski M, Torli\u0144ski L, K\u0142opocka M, Kosmowski W, et al. Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence. Alcohol Alcohol. 2000;35:91\u20137.","journal-title":"Alcohol Alcohol."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1242-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-018-1242-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1242-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T21:37:10Z","timestamp":1720906630000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-018-1242-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1242"],"URL":"https:\/\/doi.org\/10.1186\/s12916-018-1242-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]},"assertion":[{"value":"4 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MB carried out aspects of this work for her Masters in Research, the University of Manchester, UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"10"}}